Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ATP6V1B1 | P15313 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458423 | 0.82 | CYP2A6 (0.69) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL2458425 | 0.82 | CYP2A6 (0.69) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL6364565 | 0.82 | CYP2A6 (0.55) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL30721683 | 0.82 | CYP2A6 (0.55) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL6157432 | 0.82 | CYP2A6 (0.55) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL6364563 | 0.82 | CYP2A6 (0.55) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL10105480 | 0.82 | CYP2A6 (0.55) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL9471072 | 0.81 | CYP2A6 (0.62) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL15359580 | 0.79 | CYP2A6 (0.64) | CYP2A6MAPK1MAPTIDO1NPSR1 | |
| SCHEMBL287209 | 0.77 | CYP2A6 (0.49) | CYP2A6MAPK1MAPTIDO1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7267913-A | — | — | None | — | — | JP | disclosed |
| EP-1755581-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL CONDITIONS | NORTHERN SYDNEY LOCAL HEALTH DISTR (AU) | 2015-07-15 | — | — | EP | disclosed |
| WO-2010035154-A1 | RECOMBINANT PROTEINS OF EPOXIDE HYDROLASE (EH) FROM PEACH | FONDAZIONE PARCO TECNOLOGICO PADANO (IT) | 2010-04-01 | — | — | WO | disclosed |
| US-20090275077-A1 | Methods of Obtaining Optically Active Epoxides and Vicinal Diols from Styrene Oxides | OXYRANE (UK) LIMITED (GB) | 2009-11-05 | — | — | US | disclosed |
| US-20080249176-A1 | Methods and Compositions for the Treatment of Myocardial Conditions | UNIVERSIDAD POLITECNICA DE VALENCIA (ES) | 2008-10-09 | — | — | US | disclosed |
| EP-1755581-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL CONDITIONS | NORTHERN SYDNEY AND CENTRAL CO (AU) | 2008-01-02 | — | — | EP | disclosed |
| US-20070281339-A1 | Methods For Obtaining Optically Active Epoxides and Vicinal Diols From Styrene Oxides | OXYRANE UK LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| CN-1946389-A | Methods and compositions for treating myocardial disease | NORTHERN SYDNEY AND CENTRAL CO (AU) | 2007-04-11 | — | — | CN | disclosed |
| EP-1756281-A2 | METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM STYRENE EPOXIDES USING ENANTIOSELECTIVE EPOXIDE HYDROLASES DERIVED FROM YEASTS | CSIR (ZA) | 2007-02-28 | — | — | EP | disclosed |
| EP-1755581-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL CONDITIONS | Northern Sydney and Central Coast Area Health Service (AU) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005102304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL CONDITIONS | NORTHERN SYDNEY AND CENTRAL COAST AREA HEALTH SERVICE (AU) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005100569-A2 | METHODS FOR THE PREPARATION OF OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM STYRENE EPOXIDES USING ENANTIOSELECTIVE EPOXIDE HYDROLASES DERIVED FROM YEASTS | CSIR (ZA) | 2005-10-27 | — | — | WO | disclosed |
| JP-H07267913-A | PREPARATION OF SUBSTITUTED PHENYLHYDRAZONE | MERCK PATENT GMBH | 1995-10-17 | — | — | JP | disclosed |
| US-4495352-A | HYPOTENSIVE AGENTS; VASODILATION; ADRENERGIC BLOCKING ACTION | MEAD JOHNSON & COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| US-4314943-A | ANTIHYPERTENSIVE AGENTS; VASODILATORS | MEAD JOHNSON & COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
| US-4234595-A | HYPOTENSIVE AGENTS; ADRENERGIC BLOCKING AGENTS; VASODILATION | MEAD JOHNSON & COMPANY (US) | 1980-11-18 | — | — | US | disclosed |
| US-3997539-A | HYPOTENSIVE, TRANQUILIZER | AMERICAN HOECHST CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275077-A1 | Methods of Obtaining Optically Active Epoxides and Vicinal Diols from Styrene Oxides | EPHX2, EPHX1, DERA | CYP2A6 900/4885MAPK1 4536/4885MAPT 4590/4885 |
| US-20070281339-A1 | Methods For Obtaining Optically Active Epoxides and Vicinal Diols From Styrene Oxides | DERA, ERG28, EPHX2 | CYP2A6 775/4885MAPK1 3099/4885MAPT 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.